Cross Country Healthcare Reports Fourth Quarter and Year-End 2011 Results
For the year ended
"Revenue growth in our nurse and allied staffing segment was a strong
18% in the fourth quarter, but was slightly below our expectations which
were based on booking momentum maintained through October that did not
hold for the remainder of the year. At year-end we saw a return to more
normal field employee attrition levels around the holidays which
suggests travel nurses have more leverage in their schedule negotiations
with hospitals than they have had for the past several years. This is
typical in a supply-constrained environment, which is more favorable for
our business than one in which demand is constrained. However, I believe
there has also been some pushback from hospital administrators whose
2011 budgets likely did not factor in the pace of recovery in the
utilization of temporary nurse and allied labor that our 2011 results
indicate; thus bringing more focus on this expense category than existed
at the same time last year," said
"While the pace of growth in our nurse and allied staffing segment is
less rapid than it was last fall, I believe the environment is conducive
to continued strong growth for this business in 2012. This is due
primarily to an improving national labor market trend, which has
historically resulted in RNs being less willing to work as many hours,
and to a lesser extent by an accelerating opportunity to provide our
staffing services to hospitals implementing electronic medical record
technology. In addition, our clinical trial services business saw modest
top-line improvement and physician staffing was up slightly in the
fourth quarter compared to a year ago. In view of these factors, I
remain optimistic regarding our performance in 2012,"
The tax related expenses in the fourth quarter of 2011 mentioned above relate to two items pertaining to prior years. First, sales tax and other state non-income based taxes recorded in selling, general and administrative expenses were adjusted due to a change in the Company's estimate of certain prior year non-income based tax positions. Second, an adjustment to income tax expense was made to correct an overstatement of prior period deferred tax assets for share-based payments.
Nurse and
For the fourth quarter of 2011, the nurse and allied staffing business
segment (travel and per diem nurse and allied health staffing) generated
revenue of
Segment staffing volume increased 16% from the prior year quarter, but
decreased 4% sequentially from the third quarter of 2011. Travel
staffing volume increased 18% on a year-over-year basis, but decreased
2% on a sequential basis while per diem staffing volume increased 4%
year-over-year, but decreased 15% sequentially. The average revenue per
FTE per day for the fourth quarter of 2011 was
For the year-ended
Physician Staffing
For the fourth quarter of 2011, the physician staffing business segment
generated revenue of
For the year-ended
Clinical Trial Services
For the fourth quarter of 2011, the clinical trial services segment
generated revenue of
For the year-ended
Other Human Capital Management Services
For the fourth quarter of 2011, the other human capital management
services business segment (education and training and retained search)
generated revenue of
For the year-ended
Debt Outstanding and Credit Facility
During the fourth quarter of 2011, the Company reduced its debt by
Stock Repurchase Program Update
During the fourth quarter of 2011, the Company repurchased 427,043
shares of its common stock at an average cost of
Guidance for First Quarter 2012
The following statements are based on current management expectations. Such statements are forward-looking and actual results may differ materially. These statements do not include the potential impact of any future mergers, acquisitions or other business combinations, any impairment charges or valuation allowances, or significant legal proceedings. For the first quarter of 2012, the Company expects:
-
Revenue to be in the
$126 million to $128 million range. - Gross profit margin to be in the 26.5% to 27.0% range.
- Adjusted EBITDA margin to be in the 3.0% to 3.5% range. Adjusted EBITDA, a non-GAAP financial measure, is defined in the accompanying financial statement tables.
-
Earnings per diluted share to be in the range of
$0.00 to $0.01 .
Quarterly Conference Call
The Company will hold its quarterly conference call on
Non-GAAP (Generally Accepted Accounting Principles) Financial Measures
This press release and accompanying financial statement tables reference non-GAAP financial measures. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as it excludes certain items that management believes are not indicative of the Company's operating performance. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.
About
In addition to historical information, this press release contains
statements relating to our future results (including certain projections
and business trends) that are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and are subject to the "safe harbor" created by those
sections. Forward-looking statements consist of statements that are
predictive in nature, depend upon or refer to future events. Words such
as "expects", "anticipates", "intends", "plans", "believes",
"estimates", "suggests", "appears", "seeks", "will" and variations of
such words and similar expressions intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results and
performance to be materially different from any future results or
performance expressed or implied by these forward-looking statements.
These factors include, without limitation, the following: our ability to
attract and retain qualified nurses, physicians and other healthcare
personnel, costs and availability of short-term housing for our travel
nurses and physicians, demand for the healthcare services we provide,
both nationally and in the regions in which we operate, the functioning
of our information systems, the effect of existing or future government
regulation and federal and state legislative and enforcement initiatives
on our business, our clients' ability to pay us for our services, our
ability to successfully implement our acquisition and development
strategies, the effect of liabilities and other claims asserted against
us, the effect of competition in the markets we serve, our ability to
successfully defend the Company, its subsidiaries, and its officers and
directors on the merits of any lawsuit or determine its potential
liability, if any, and other factors set forth in Item 1A. "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended
December 31, 2010, and our other
Although we believe that these statements are based upon reasonable
assumptions, we cannot guarantee future results and readers are
cautioned not to place undue reliance on these forward-looking
statements, which reflect management's opinions only as of the date of
this press release. There can be no assurance that (i) we have correctly
measured or identified all of the factors affecting our business or the
extent of these factors' likely impact, (ii) the available information
with respect to these factors on which such analysis is based is
complete or accurate, (iii) such analysis is correct or (iv) our
strategy, which is based in part on this analysis, will be successful.
The Company undertakes no obligation to update or revise forward-looking
statements. All references to "we," "us," "our," or "Cross Country" in
this press release mean
|
|||||||||||||||||||||||||||||||||
Consolidated Statements of Operations (a) |
|||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands, except per share data) | |||||||||||||||||||||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
2011 | 2010 | % Change | 2011 | 2010 | % Change | ||||||||||||||||||||||||||||
Revenue from services | $ | 124,729 | $ | 113,677 | 10% | $ | 503,986 | $ | 468,562 | 8% | |||||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||||||||||
Direct operating expenses | 90,115 | 81,079 | 11% | 366,044 | 336,250 | 9% | |||||||||||||||||||||||||||
Selling, general and administrative expenses (b) | 29,131 | 27,147 | 7% | 116,538 | 108,984 | 7% | |||||||||||||||||||||||||||
Bad debt expense | 344 | 179 | 92% | 579 | 294 | 97% | |||||||||||||||||||||||||||
Depreciation | 1,598 | 1,887 | (15%) | 6,791 | 8,043 | (16%) | |||||||||||||||||||||||||||
Amortization | 818 | 964 | (15%) | 3,493 | 3,851 | (9%) | |||||||||||||||||||||||||||
Impairment charges (c) | - | 10,764 | (100%) | - | 10,764 | (100%) | |||||||||||||||||||||||||||
Total operating expenses | 122,006 | 122,020 | 0% | 493,445 | 468,186 | 5% | |||||||||||||||||||||||||||
Income (loss) from operations | 2,723 | (8,343 | ) | NM | 10,541 | 376 |
NM |
||||||||||||||||||||||||||
Other (income) expenses: | |||||||||||||||||||||||||||||||||
Foreign exchange (gain) loss | (122 | ) | 4 | NM | (247 | ) | 76 | NM | |||||||||||||||||||||||||
Interest expense | 676 | 805 | (16%) | 2,856 | 4,245 | (33%) | |||||||||||||||||||||||||||
Other income, net | (70 | ) | (50 | ) | 40% | (298 | ) | (173 | ) | 72% | |||||||||||||||||||||||
Income (loss) before income taxes | 2,239 | (9,102 | ) | NM | 8,230 | (3,772 | ) | NM | |||||||||||||||||||||||||
Income tax expense (benefit) (b) | 1,707 | (3,098 | ) | NM | 4,132 | (997 | ) | NM | |||||||||||||||||||||||||
Net income (loss) |
$ | 532 | $ | (6,004 | ) | NM | $ | 4,098 | $ | (2,775 | ) | NM | |||||||||||||||||||||
Net income (loss) per common share: |
|||||||||||||||||||||||||||||||||
Basic | $ | 0.02 | $ | (0.19 | ) | NM | $ | 0.13 | $ | (0.09 | ) | NM | |||||||||||||||||||||
Diluted | $ | 0.02 | $ | (0.19 | ) | NM | $ | 0.13 | $ | (0.09 | ) | NM | |||||||||||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||||||||||||||
Basic | 31,108 | 31,103 | 31,146 | 31,060 | |||||||||||||||||||||||||||||
Diluted | 31,117 | 31,103 | 31,192 | 31,060 | |||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures | |||||||||||||||||||||||||||||||||
Adjusted EBITDA (d) | |||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands) | |||||||||||||||||||||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
2011 | 2010 | 2011 | 2010 | ||||||||||||||||||||||||||||||
Income (loss) from operations |
$ | 2,723 | $ | (8,343 | ) | $ | 10,541 | $ | 376 | ||||||||||||||||||||||||
Depreciation | 1,598 | 1,887 | 6,791 | 8,043 | |||||||||||||||||||||||||||||
Amortization | 818 | 964 | 3,493 | 3,851 | |||||||||||||||||||||||||||||
Impairment charges (c) | - | 10,764 | - | 10,764 | |||||||||||||||||||||||||||||
Equity compensation | 645 | 715 | 2,895 | 2,657 | |||||||||||||||||||||||||||||
Adjusted EBITDA (d) | $ | 5,784 | $ | 5,987 | $ | 23,720 | $ | 25,691 | |||||||||||||||||||||||||
Adjusted EBITDA Margin (d) | 4.6 | % | 5.3 | % | 4.7 | % | 5.5 | % | |||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Condensed Consolidated Balance Sheets (a) | |||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands) | |||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
2011 | 2010 | ||||||||||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||
Current assets: | |||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 10,648 | $ | 10,957 | |||||||||||||||||||||||||||||
Short-term cash investments | 1,691 | 1,870 | |||||||||||||||||||||||||||||||
Accounts receivable, net | 71,802 | 64,395 | |||||||||||||||||||||||||||||||
Deferred tax assets | 10,645 | 11,801 | |||||||||||||||||||||||||||||||
Income taxes receivable | 1,879 | 6,563 | |||||||||||||||||||||||||||||||
Prepaid expenses | 7,441 | 6,530 | |||||||||||||||||||||||||||||||
Other current assets | 701 | 649 | |||||||||||||||||||||||||||||||
Total current assets | 104,807 | 102,765 | |||||||||||||||||||||||||||||||
Property and equipment, net | 12,018 | 14,536 | |||||||||||||||||||||||||||||||
Trademarks, net | 52,053 | 52,055 | |||||||||||||||||||||||||||||||
Goodwill, net | 143,344 | 143,349 | |||||||||||||||||||||||||||||||
Other identifiable intangible assets, net | 21,195 | 24,681 | |||||||||||||||||||||||||||||||
Debt issuance costs, net | 1,199 | 2,112 | |||||||||||||||||||||||||||||||
Non-current deferred tax assets | - | 2,484 | |||||||||||||||||||||||||||||||
Other long-term assets | 1,294 | 1,676 | |||||||||||||||||||||||||||||||
Total assets | $ | 335,910 | $ | 343,658 | |||||||||||||||||||||||||||||
Liabilities and Stockholders' Equity | |||||||||||||||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||||||||||||||
Accounts payable and accrued expenses | $ | 9,018 | $ | 7,944 | |||||||||||||||||||||||||||||
Accrued employee compensation and benefits | 16,332 | 14,641 | |||||||||||||||||||||||||||||||
Current portion of long-term debt | 16,998 | 7,957 | |||||||||||||||||||||||||||||||
Other current liabilities | 4,002 | 4,712 | |||||||||||||||||||||||||||||||
Total current liabilities | 46,350 | 35,254 | |||||||||||||||||||||||||||||||
Long-term debt | 25,048 | 45,556 | |||||||||||||||||||||||||||||||
Non-current deferred tax liabilities | 58 | - | |||||||||||||||||||||||||||||||
Other long-term liabilities | 15,154 | 16,839 | |||||||||||||||||||||||||||||||
Total liabilities | 86,610 | 97,649 | |||||||||||||||||||||||||||||||
Commitments and contingencies | |||||||||||||||||||||||||||||||||
Stockholders' equity: | |||||||||||||||||||||||||||||||||
Common stock | 3 | 3 | |||||||||||||||||||||||||||||||
Additional paid-in capital | 243,170 | 243,005 | |||||||||||||||||||||||||||||||
Accumulated other comprehensive loss | (3,373 | ) | (2,401 | ) | |||||||||||||||||||||||||||||
Retained earnings | 9,500 | 5,402 | |||||||||||||||||||||||||||||||
Total stockholders' equity | 249,300 | 246,009 | |||||||||||||||||||||||||||||||
Total liabilities and stockholders' equity | $ | 335,910 | $ | 343,658 | |||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Segment Data (e) | |||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands) | |||||||||||||||||||||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
2011 | % of Total | 2010 | % of Total | % Change | 2011 | % of Total | 2010 | % of Total | % Change | ||||||||||||||||||||||||
Revenue from services: | |||||||||||||||||||||||||||||||||
Nurse and allied staffing | $ | 70,287 | 56 | % | $ | 59,417 | 52 | % | 18% | $ | 278,793 | 55 | % | $ | 242,160 | 52 | % | 15% | |||||||||||||||
Physician staffing | 27,928 | 22 | % | 27,895 | 25 | % | 0% | 118,781 | 24 | % | 121,599 | 26 | % | (2%) | |||||||||||||||||||
Clinical trial services | 15,738 | 13 | % | 15,301 | 13 | % | 3% | 64,609 | 13 | % | 61,957 | 13 | % | 4% | |||||||||||||||||||
Other human capital management services | 10,776 | 9 | % | 11,064 | 10 | % | (3%) | 41,803 | 8 | % | 42,846 | 9 | % | (2%) | |||||||||||||||||||
$ | 124,729 | 100 | % | $ | 113,677 | 100 | % | 10% | $ | 503,986 | 100 | % | $ | 468,562 | 100 | % | 8% | ||||||||||||||||
Contribution income (f) | |||||||||||||||||||||||||||||||||
Nurse and allied staffing (g) | $ | 5,473 | $ | 5,224 | 5% | $ | 22,441 | $ | 21,383 | 5% | |||||||||||||||||||||||
Physician staffing | 2,720 | 2,958 | (8%) | 11,320 | 13,052 | (13%) | |||||||||||||||||||||||||||
Clinical trial services | 1,472 | 1,336 | 10% | 6,555 | 6,391 | 3% | |||||||||||||||||||||||||||
Other human capital management services | 852 | 1,279 | (33%) | 3,172 | 3,768 | (16%) | |||||||||||||||||||||||||||
10,517 | 10,797 | (3%) | 43,488 | 44,594 | (2%) | ||||||||||||||||||||||||||||
Unallocated corporate overhead (g) | 5,378 | 5,525 | (3%) | 22,663 | 21,560 | 5% | |||||||||||||||||||||||||||
Depreciation | 1,598 | 1,887 | (15%) | 6,791 | 8,043 | (16%) | |||||||||||||||||||||||||||
Amortization | 818 | 964 | (15%) | 3,493 | 3,851 | (9%) | |||||||||||||||||||||||||||
Impairment charges (c) | - | 10,764 | (100%) | - | 10,764 | (100%) | |||||||||||||||||||||||||||
Income (loss) from operations |
$ | 2,723 | $ | (8,343 | ) | NM | $ | 10,541 | $ | 376 |
NM |
||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Other Financial Data | |||||||||||||||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
2011 | 2010 | 2011 | 2010 | ||||||||||||||||||||||||||||||
Net cash provided by operating activities (in thousands) | $ | 3,666 | $ | 6,737 | $ | 18,296 | $ | 31,522 | |||||||||||||||||||||||||
Nurse and allied staffing statistical data: |
|||||||||||||||||||||||||||||||||
FTEs (h) | 2,457 | 2,124 | 2,472 | 2,185 | |||||||||||||||||||||||||||||
Days worked (i) | 226,044 | 195,408 | 902,280 | 797,525 | |||||||||||||||||||||||||||||
Average nurse and allied staffing revenue per FTE per day (j) | $ | 311 | $ | 304 | $ | 309 | $ | 304 | |||||||||||||||||||||||||
Physician staffing statistical data (k): |
|||||||||||||||||||||||||||||||||
Days filled (l) | 20,200 | 20,350 | 85,416 | 89,421 | |||||||||||||||||||||||||||||
Revenue per day filled (m) | $ | 1,383 | $ | 1,371 | $ | 1,391 | $ | 1,360 | |||||||||||||||||||||||||
(a) Certain prior year data has been reclassified to conform to the current year's presentation. | |||||||||||||||||||||||||||||||||
(b) During the fourth quarter of 2011, the Company accrued a
pretax liability for certain non-income tax matters related to
prior years of approximately |
|||||||||||||||||||||||||||||||||
(c) Impairment charges in the three months and year ended |
|||||||||||||||||||||||||||||||||
(d) Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, is defined as income from operations before depreciation, amortization and non-cash equity compensation. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to income from operations as an indicator of operating performance. Management uses Adjusted EBITDA as one performance measure in its annual cash incentive program for certain members of its management team. In addition, management monitors Adjusted EBITDA for planning purposes, including compliance with its debt covenants. Adjusted EBITDA, as defined, closely matches the operating measure used in the Company's Debt Leverage Ratio and Minimum Fixed Charge Coverage Ratio as defined by its Credit Agreement. Management believes Adjusted EBITDA, as defined, is useful to investors when evaluating the Company's performance as it excludes certain items that management believes are not indicative of the Company's operating performance. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue. |
|||||||||||||||||||||||||||||||||
(e) Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC. | |||||||||||||||||||||||||||||||||
(f) Defined as income from operations before depreciation, amortization and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance. |
|||||||||||||||||||||||||||||||||
(g) Certain 2010 segment data has been reclassified to conform to the 2011 presentation. During 2011, the Company refined its methodology for allocating certain corporate overhead expenses to its nurse and allied staffing segment to more accurately reflect that segment's profitability. |
|||||||||||||||||||||||||||||||||
(h) FTEs represent the average number of nurse and allied contract staffing personnel on a full-time equivalent basis. | |||||||||||||||||||||||||||||||||
(i) Days worked is calculated by multiplying the FTEs by the number of days during the respective period. | |||||||||||||||||||||||||||||||||
(j) Average revenue per FTE per day is calculated by dividing the nurse and allied staffing revenue by the number of days worked in the respective periods. Nurse and allied staffing revenue also includes revenue from permanent placement of nurses. |
|||||||||||||||||||||||||||||||||
(k) Beginning in the first quarter of 2011, the Company refined its statistical methodology related to its physician staffing metrics. Accordingly, historical 2010 quarterly data for these metrics have been revised to conform to the current year's presentation. |
|||||||||||||||||||||||||||||||||
(l) Days filled is calculated by dividing the total hours filled during the period by 8 hours. | |||||||||||||||||||||||||||||||||
(m) Revenue per day filled is calculated by dividing the applicable revenue generated by the Company's physician staffing segment by days filled for the period presented. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
NM - Not meaningful |
Director/Investor
& Corporate Relations
hgoldman@crosscountry.com
Source:
News Provided by Acquire Media